Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2025. "2025 demonstrated the momentum we built as a business,” commented ...

Viral vector gene therapy represents a rapidly advancing field at the intersection of molecular medicine, biotechnology, and clinical translation. Viral ...

First ZEVASKYN® commercial patient treatment completed in December -- ZEVASKYN launch momentum building in first quarter 2026 –- $191.4M in ...

In this webinar, Celeste Nelson and Oscar Abilez will discuss some of the latest approaches to overcoming setbacks in growing ...

A small survey in Germany found many men with severe hemophilia are not interested in gene therapy, which may suggest gaps in patient info.

Bhubaneswar: Members of the Odisha Duchenne Muscular Dystrophy Association (ODMDA) Wednesday submitted a letter to the Health ...

Good morning, everyone, and welcome to the Abeona Therapeutics Full Year 2025 Results Conference Call. [Operator Instructions] Please note this conference is being recor ...

First ZEVASKYN- commercial patient treatment completed in December - - ZEVASKYN launch momentum building in first quarter 2026 - - $191.4M in cash, cash equivalents and short-term investments as of ...

Abeona Therapeutics (NASDAQ:ABEO) executives said the company is seeing growing patient demand for ZEVASKYN, an autologous ...

Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2025 Earnings Call Transcript March 17, 2026 Abeona Therapeutics Inc. beats ...

From a bill to make Diwali a ceremonial holiday, to setting a first responder definition and new Title IX role – here’s what to know from Leg Hall.

He switched to Brightspeed in December 2025, agreeing to a yearlong contract for 2GB internet service at $59.99 a month. He ...